Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Arthromir is a multi-ingredient dietary supplement (nutraceutical) developed by the Russian company MIRRA to support joint health and manage symptoms of musculoskeletal disorders such as osteoarthritis. The formulation typically includes glucosamine sulfate and chondroitin sulfate, which serve as essential building blocks for the synthesis and maintenance of articular cartilage. Additionally, it incorporates botanical extracts, most notably willow bark (*Salix alba*), which contains salicin—a natural precursor to salicylic acid that acts as a non-selective inhibitor of cyclooxygenase (COX) enzymes to provide anti-inflammatory and analgesic effects. Other components like horsetail extract provide organic silica to support connective tissue integrity. Arthromir is intended to improve joint lubrication, reduce stiffness, and slow the progression of degenerative joint changes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Arthromir.